• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2022年在霍拉马巴德沙希德·拉希米医院评估局部晚期管腔A型患者与三阴性患者的复发率:一项横断面研究。

Assessing the recurrence rate in locally advanced Luminal A patients compared to triple-negative patients in Shahid Rahimi Hospital Khorramabad in 2022: a cross-sectional study.

作者信息

Joudaki Mohammad, Khani Parya, Farokhi Simin, Ahmadi Somaghian Shahram, Rahimi Sarah, Beiranvand Mania, Mokhayeri Yaser, Pajouhi Ali

机构信息

Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.

Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.

出版信息

Ann Med Surg (Lond). 2025 May 13;87(6):3123-3127. doi: 10.1097/MS9.0000000000003338. eCollection 2025 Jun.

DOI:10.1097/MS9.0000000000003338
PMID:40486586
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12140775/
Abstract

BACKGROUND

Breast cancer is one of the most common causes of cancer death in women both globally and in Iran. Although medical breakthroughs have improved its prognosis, different characteristics can vary locally, especially in understudied regions. Therefore, the present study was designed and carried out in 2022 to compare the rate of breast cancer recurrence in Luminal A and triple-negative patients referred to the Shahid Rahimi Hospital in Khorramabad from March 2019 to March 2020.

MATERIALS AND METHODS

This study was a descriptive-analytical cross-sectional study designed and conducted on 59 patients diagnosed with Luminal A and triple-negative breast cancer treated at the Shahid Rahimi Hospital from March 2019 to March 2020. In this study, the data collection instrument was a researcher-designed form that included information such as age, history of recurrence, type of cancer, family history of cancer, personal history of cancer, lymph node involvement, hookah use history, smoking history, breastfeeding history, and material status. Finally, after collecting information, data was analyzed using SPSS software version 25.

RESULTS

The average age of the patients in this study was 49.45 ± 6.01 years, and the youngest and oldest patients were 35 and 62 years, respectively. Among the studied patients, 34 individuals (57.63%) had Luminal A cancer, and 25 patients (42.37%) had triple negative cancer. Recurrence was reported in 23 patients (38.98%), and lymph node involvement was reported in 21 patients (35.59%). Moreover, 14 patients (23.73%) were positive for a personal history of cancer, and 22 patients (37.29%) had a family history of cancer. In this study, the relationship between recurrence and type of cancer and involvement of lymph nodes was statistically significant ( < 0.05).

CONCLUSION

The rate of recurrence in patients with Luminal A cancer was higher than in patients with triple-negative cancer, according to the results of the study. More attention and periodic examinations in terms of recurrence in patients with Luminal A cancer were necessary.

摘要

背景

乳腺癌是全球及伊朗女性癌症死亡的最常见原因之一。尽管医学突破改善了其预后,但不同特征在局部地区可能存在差异,尤其是在研究较少的地区。因此,本研究于2022年设计并开展,旨在比较2019年3月至2020年3月转诊至霍拉马巴德沙希德拉希米医院的Luminal A型和三阴性乳腺癌患者的复发率。

材料与方法

本研究为描述性分析横断面研究,对2019年3月至2020年3月在沙希德拉希米医院接受治疗的59例诊断为Luminal A型和三阴性乳腺癌的患者进行设计和实施。在本研究中,数据收集工具是研究者设计的表格,包括年龄、复发史、癌症类型、癌症家族史、个人癌症史、淋巴结受累情况、水烟使用史、吸烟史、母乳喂养史和物质状态等信息。最后,收集信息后,使用SPSS 25版软件进行数据分析。

结果

本研究患者的平均年龄为49.45±6.01岁,最年轻和最年长的患者分别为35岁和62岁。在研究的患者中,34例(57.63%)患有Luminal A型癌症,25例(42.37%)患有三阴性癌症。23例(38.98%)报告有复发,21例(35.59%)报告有淋巴结受累。此外,14例(23.73%)有个人癌症史呈阳性,22例(37.29%)有癌症家族史。在本研究中,复发与癌症类型和淋巴结受累之间的关系具有统计学意义(<0.05)。

结论

根据研究结果,Luminal A型癌症患者的复发率高于三阴性癌症患者。有必要对Luminal A型癌症患者的复发给予更多关注并进行定期检查。

相似文献

1
Assessing the recurrence rate in locally advanced Luminal A patients compared to triple-negative patients in Shahid Rahimi Hospital Khorramabad in 2022: a cross-sectional study.2022年在霍拉马巴德沙希德·拉希米医院评估局部晚期管腔A型患者与三阴性患者的复发率:一项横断面研究。
Ann Med Surg (Lond). 2025 May 13;87(6):3123-3127. doi: 10.1097/MS9.0000000000003338. eCollection 2025 Jun.
2
[Clinicopathological characteristics and prognosis of different molecular types of breast cancer].[不同分子类型乳腺癌的临床病理特征及预后]
Zhonghua Yi Xue Za Zhi. 2016 Jun 14;96(22):1733-7. doi: 10.3760/cma.j.issn.0376-2491.2016.22.004.
3
[The influence of molecular classification of breast cancer on the safety of breast-conserving surgery].[乳腺癌分子分类对保乳手术安全性的影响]
Zhonghua Zhong Liu Za Zhi. 2018 May 23;40(5):341-346. doi: 10.3760/cma.j.issn.0253-3766.2018.05.005.
4
An epidemiological investigation of gallstone disease among patients admitted to Shahid Rahimi teaching hospital in Khorramabad in 2016-2020.2016-2020 年期间入住霍拉马巴德沙希德·拉希米教学医院的患者胆石病的流行病学调查。
Afr Health Sci. 2023 Jun;23(2):435-441. doi: 10.4314/ahs.v23i2.50.
5
Clinicopathological features of indonesian breast cancers with different molecular subtypes.不同分子亚型的印度尼西亚乳腺癌的临床病理特征
Asian Pac J Cancer Prev. 2014;15(15):6109-13. doi: 10.7314/apjcp.2014.15.15.6109.
6
Association between common risk factors and molecular subtypes in breast cancer patients.乳腺癌患者常见风险因素与分子亚型的相关性。
Breast. 2013 Jun;22(3):344-50. doi: 10.1016/j.breast.2012.08.005. Epub 2012 Sep 14.
7
Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative.乳腺癌不同分子亚型中的淋巴结状态:三阴性肿瘤更有可能无淋巴结转移。
Oncotarget. 2017 Feb 2;8(33):55534-55543. doi: 10.18632/oncotarget.15022. eCollection 2017 Aug 15.
8
Breast cancer recurrence according to molecular subtype.根据分子亚型的乳腺癌复发情况。
Asian Pac J Cancer Prev. 2014;15(14):5539-44. doi: 10.7314/apjcp.2014.15.14.5539.
9
Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy.乳腺癌亚型、年龄及淋巴结状态作为保乳治疗后局部复发的预测因素。
Breast Cancer Res Treat. 2017 Jan;161(1):173-179. doi: 10.1007/s10549-016-4031-5. Epub 2016 Nov 3.
10
Patterns of regional recurrence according to molecular subtype in patients with pN2 breast cancer treated with limited field regional irradiation.接受局部区域照射治疗的pN2期乳腺癌患者按分子亚型划分的区域复发模式
Jpn J Clin Oncol. 2023 Jan 6;53(1):57-62. doi: 10.1093/jjco/hyac161.

本文引用的文献

1
A global perspective on the ethnic-specific variation and its implication in clinical application.关于种族特异性变异及其在临床应用中的意义的全球视角。
J Natl Cancer Cent. 2022 Dec 15;3(1):14-20. doi: 10.1016/j.jncc.2022.12.001. eCollection 2023 Mar.
2
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.基于曲妥珠单抗的抗体药物偶联物的安全性概况:对欧洲药品不良反应数据库(EudraVigilance)中登记的真实世界数据的分析
Biomedicines. 2024 Apr 25;12(5):953. doi: 10.3390/biomedicines12050953.
3
Plasma Circulating Terminal Differentiation-Induced Non-Coding RNA Serves as a Biomarker in Breast Cancer.血浆循环终末分化诱导非编码RNA作为乳腺癌的生物标志物
Int J Hematol Oncol Stem Cell Res. 2024 Jan 1;18(1):1-6. doi: 10.18502/ijhoscr.v18i1.14739.
4
Reply on "Prognosis according to the timing of recurrence in breast cancer" (Ann Surg Treat Res 2023;104:1-9).对《乳腺癌复发时间的预后分析》(《外科治疗与研究杂志》2023年;104:1-9)的回复
Ann Surg Treat Res. 2024 Apr;106(4):239-240. doi: 10.4174/astr.2024.106.4.239. Epub 2024 Mar 29.
5
Breast cancer organoids derived from patients: A platform for tailored drug screening.患者来源的乳腺癌类器官:用于定制药物筛选的平台。
Biochem Pharmacol. 2023 Nov;217:115803. doi: 10.1016/j.bcp.2023.115803. Epub 2023 Sep 13.
6
Long-term locoregional recurrence in patients treated for breast cancer.乳腺癌治疗患者的长期局部区域复发
Breast Cancer Res Treat. 2023 Dec;202(3):551-561. doi: 10.1007/s10549-023-07089-6. Epub 2023 Sep 14.
7
Economic burden of breast cancer: a case of Southern Iran.乳腺癌的经济负担:以伊朗南部为例。
Cost Eff Resour Alloc. 2023 Aug 29;21(1):58. doi: 10.1186/s12962-023-00470-8.
8
Advances in systemic therapies for triple negative breast cancer.三阴性乳腺癌的系统治疗进展。
BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674.
9
Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence.同侧乳腺癌复发患者的临床病程和后续复发及生存的预测因素。
Cancer Control. 2022 Jan-Dec;29:10732748221089412. doi: 10.1177/10732748221089412.
10
STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.STROCSS 2021:加强外科学队列研究、横断面研究和病例对照研究报告规范。
Int J Surg. 2021 Dec;96:106165. doi: 10.1016/j.ijsu.2021.106165. Epub 2021 Nov 11.